NCT06197126View on ClinicalTrials.gov

MRI-based Signatures for Survival Prediction in Cervical Cancer With Radiotherapy

Not yet recruitingOBSERVATIONAL
Enrollment

200

Participants

Timeline

Start Date

January 1, 2024

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2028

Conditions
Cervical CancerRadiotherapyPrognostic ModelMRI
Interventions
RADIATION

Treatment mainly composed of external pelvic beam radiotherapy (EBRT) followed by individualized high-dose-rate intracavitary brachytherapy (HDR-ICBT) .

The chemotherapy regimens included cisplatin (40 mg/m2) or nedaplatin (80 mg/m2) monotherapy or combined with paclitaxel (135 mg/m2) every three weeks during radiotherapy.

Trial Locations (1)

350014

Fujian Cancer Hospital, Fuzhou

All Listed Sponsors
lead

Fujian Cancer Hospital

OTHER_GOV

NCT06197126 - MRI-based Signatures for Survival Prediction in Cervical Cancer With Radiotherapy | Biotech Hunter | Biotech Hunter